Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
William A. Fischer, Joseph J. Eron, Wayne Holman, et al.
Science Translational Medicine (2021) Vol. 14, Iss. 628
Open Access | Times Cited: 297

Showing 1-25 of 297 citing articles:

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
Ben Killingley, Alex Mann, Mariya Kalinova, et al.
Nature Medicine (2022) Vol. 28, Iss. 5, pp. 1031-1041
Open Access | Times Cited: 422
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
Laura Vangeel, Winston Chiu, Steven De Jonghe, et al.
Antiviral Research (2022) Vol. 198, pp. 105252-105252
Open Access | Times Cited: 384
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Christopher Butler, Richard Hobbs, Oghenekome Gbinigie, et al.
The Lancet (2022) Vol. 401, Iss. 10373, pp. 281-293
Open Access | Times Cited: 316
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Sho Iketani, Hiroshi Mohri, Bruce Culbertson, et al.
Nature (2022) Vol. 613, Iss. 7944, pp. 558-564
Open Access | Times Cited: 306
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
The Lancet (2022) Vol. 400, Iss. 10359, pp. 1213-1222
Open Access | Times Cited: 243
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 12, pp. 1681-1693
Open Access | Times Cited: 218
Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
Anoop Narayanan, M. Narwal, Sydney A. Majowicz, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 173
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 8, pp. 1403-1411
Open Access | Times Cited: 116
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
Pan-Pan Zhou, Ge Song, Hejun Liu, et al.
Immunity (2023) Vol. 56, Iss. 3, pp. 669-686.e7
Open Access | Times Cited: 113
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 10
Open Access | Times Cited: 99
SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice
Kenneth H. Dinnon, Sarah R. Leist, Kenichi Okuda, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 664
Open Access | Times Cited: 92
The mechanism of RNA capping by SARS-CoV-2
Gina J. Park, Adam Osinski, Genaro Hernandez, et al.
Nature (2022)
Open Access | Times Cited: 89
Stopping pandemics before they start: Lessons learned from SARS-CoV-2
A.M. Edwards, Ralph S. Baric, Erica Ollmann Saphire, et al.
Science (2022) Vol. 375, Iss. 6585, pp. 1133-1139
Open Access | Times Cited: 82
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Molnupiravir: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 4, pp. 455-460
Open Access | Times Cited: 77
Impact of COVID-19 on Cardiovascular Disease
Ivan Vosko, Andreas Zirlik, Heiko Bugger
Viruses (2023) Vol. 15, Iss. 2, pp. 508-508
Open Access | Times Cited: 63
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
William HK Schilling, Podjanee Jittamala, James A Watson, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 1, pp. 36-45
Open Access | Times Cited: 55
Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2
Yosuke Hirotsu, Hiroaki Kobayashi, Yumiko Kakizaki, et al.
Med (2023) Vol. 4, Iss. 11, pp. 813-824.e4
Open Access | Times Cited: 49
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
Thales Kronenberger, Stefan Laufer, Thanigaimalai Pillaiyar
Drug Discovery Today (2023) Vol. 28, Iss. 6, pp. 103579-103579
Open Access | Times Cited: 40
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir
Jacqueline G. Gerhart, Donna S. Cox, Ravi Shankar Prasad Singh, et al.
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 1, pp. 27-42
Open Access | Times Cited: 20
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Joseph F. Standing, Laura Buggiotti, José Afonso Guerra‐Assunção, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 18
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
Viravarn Luvira, William HK Schilling, Podjanee Jittamala, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 16
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top